RAD52

DNA repair protein RAD52 homolog · P43351 · RAD52 on Sugi Atlas →

136,263 patent compounds predicted against RAD52, 96,874 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Prochlorperazine (SCHEMBL40855)	1.00	5/20
Thiethylperazine (SCHEMBL41676)	0.78	5/20
Thiethylperazine (SCHEMBL41678)	0.78	5/20
Thiethylperazine (SCHEMBL49124)	0.78	5/20
Thiethylperazine (SCHEMBL41677)	0.73	5/20
Berberine (SCHEMBL25632)	1.00	4/20
Fluphenazine (SCHEMBL41634)	1.00	4/20
Fluphenazine (SCHEMBL41635)	1.00	4/20
Amsacrine (SCHEMBL4047)	0.98	4/20
Chlorprothixene (SCHEMBL24133)	0.72	4/20
Chlorprothixene (SCHEMBL94235)	0.72	4/20
Chlorprothixene (SCHEMBL94236)	0.72	4/20
Acetophenazine (SCHEMBL94266)	0.69	4/20
Pipamazine (SCHEMBL49665)	0.69	4/20
Nitracrine (SCHEMBL8807)	0.65	4/20
SCHEMBL6931	0.46	4/20
Pinafide (SCHEMBL18697)	1.00	3/20
Benzethonium (SCHEMBL21713)	1.00	3/20
Trifluoperazine (SCHEMBL24866)	1.00	3/20
Ranitidine (SCHEMBL33298)	1.00	3/20

Clinical trials — most relevant to RAD52 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)	PHASE2	RECRUITING
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation	PHASE2	UNKNOWN
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA	PHASE2	ACTIVE_NOT_RECRUITING
Niraparib and Dostarlimab in HRD Solid Tumors	PHASE2	UNKNOWN
Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)	PHASE2	COMPLETED
Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients.	PHASE2	ACTIVE_NOT_RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate Cancer	PHASE2	UNKNOWN
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations	PHASE2	RECRUITING
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer	PHASE2	WITHDRAWN
Olaparib In Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)	PHASE1/PHASE2	RECRUITING
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.	PHASE2	ACTIVE_NOT_RECRUITING
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)	PHASE2	UNKNOWN
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Precision-Based Genomics in Prostate Cancer	nan	RECRUITING
Prognostic Biomarkers in Patients With Urothelial Carcinoma	nan	COMPLETED
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RAD52 binder may also engage these)

Protein	Name	Similarity
P39022	—	0.998	P39022 →
P43352	—	0.998	P43352 →
Q9QZ11	—	0.991	Q9QZ11 →
Q9NQW6	—	0.991	Q9NQW6 →
Q08E13	—	0.990	Q08E13 →
O43310	—	0.990	O43310 →
O42905	—	0.990	O42905 →
P46200	—	0.990	P46200 →
P61406	—	0.989	P61406 →
Q15329	—	0.989	Q15329 →
Q6A037	—	0.989	Q6A037 →
A0JMK9	—	0.989	A0JMK9 →
Q5TKR9	—	0.989	Q5TKR9 →
Q3ULB5	—	0.989	Q3ULB5 →
Q5HZN1	—	0.989	Q5HZN1 →
A5D979	—	0.989	A5D979 →
RNF10	E3 ubiquitin-protein ligase RNF10	0.988	landscape →
Q6DJS0	—	0.988	Q6DJS0 →
Q9I920	—	0.988	Q9I920 →
Q803U7	—	0.988	Q803U7 →
A6QP06	—	0.988	A6QP06 →
Q4V882	—	0.988	Q4V882 →
P10244	—	0.988	P10244 →
Q9H7E2	—	0.988	Q9H7E2 →
A9JR78	—	0.988	A9JR78 →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.988	landscape →
Q9BWF2	—	0.987	Q9BWF2 →
Q80XI3	—	0.987	Q80XI3 →
Q5HZJ0	—	0.987	Q5HZJ0 →
Q92539	—	0.987	Q92539 →